// App-Quantinova.ai

8394 : Patient-Reported Outcomes from NOVA: A Randomized Controlled Study of the Efficacy of Natalizumab 6-Week Dosing Vs Continued 4-Week Dosing for MS

Researchers

Presenter

  • Lana Zhovtis Ryerson

Principal Investigators

  • Gilles Defer

  • Jeffrey A Cohen

  • Douglas L Arnold

  • Helmut Butzkueven

  • Gary Cutter

  • Gavin Giovannoni

  • Joep Killestein

  • Heinz Wiendl

  • John Foley

  • George Kong

  • Susie Sinks

  • Robert Kuhelj

  • Tyler Lasky

  • Karthik Bodhinathan

Medical Centers

  • Biogen, Cambridge, MA

  • Montreal Neurological Institute, McGill University and NeuroRx Research Inc., Montreal, QC, CANADA

  • Mellen Center, Cleveland Clinic, Cleveland, OH

  • Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK

  • Department of Hematology, Centre Hospitalier Universitaire Caen, Caen, France

  • Biogen, Baar, Sweden

  • Department of Neurology, NYU Langone Health, New York University, New York, NY

  • Department of Hematology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, Netherlands

  • Rocky Mountain MS Clinic, Salt Lake City, UT

  • University Hospital of Muenster, Muenster, Germany

  • Univ of Alabama Sch of Public Health, Birmingham, AL

  • Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia

Locations

  • United States

  • Germany

  • Sweden

  • Australia

  • France

  • United Kingdom

  • Netherlands

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Multiple Sclerosis

Biomarkers

  • N/A

Drug/Treatment

  • Natalizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • NA

Study Id's

  • NCT03689972

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved